Sanofi announced on Wednesday that it had received approval from the European Medicines Authority for Dupixent, its treatment for uncontrolled chronic obstructive pulmonary disease (COPD).

COPD, also known as "smoker's cough", is a potentially fatal disease affecting 35 million people in Europe and 16 million Americans.

The U.S. Food and Drug Administration (FDA) has postponed its decision until May, pending further data.

(Written by Pauline Foret, edited by Augustin Turpin)